Recommendations from the EGAPP Working Group: Testing for Cytochrome P450 Polymorphisms in Adults with Nonpsychotic Depression Treated with Selective Serotonin Reuptake Inhibitors
Publication Date: December 2007
Publisher(s): American College of Medical Genetics
Keywords: P450; SSRI; CYP450; Pharmacogenetics
Coverage: United States
This statement summarizes the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommendations regarding CYP450 genetic testing in adult patients beginning treatment with selective serotonin reuptake inhibitors (SSRIs), and the supporting scientific evidence.
EGAPP is a project developed by the National Office of Public Health Genomics at the Centers for Disease Control and Prevention to support a rigorous, evidence-based process for evaluating genetic tests and other genomic applications that are in transition from research to clinical and public health practice in the United States. A key goal of the EGAPP Working Group is to develop conclusions and recommendations regarding clinical genomic applications and to establish clear linkage to the supporting scientific evidence.
The Working Group members are nonfederal experts in genetics, laboratory medicine, and clinical epidemiology convened to establish methods and processes; set priorities for review topics; participate in technical expert panels for commissioned evidence reviews; publish recommendations; and provide guidance and feedback on other project activities.
In Genetics in Medicine, vol.9:12, December 2007, pl819-825.